Therapeutics in hospitalised adult patients with COVID-19

Abstract

The proportion of patients with COVID-19 requiring hospitalisation has decreased dramatically since the start of the pandemic, while the population has been gaining immunity. In parallel, variants have also evolved. Most patients included in large-scale RCTs were recruited during the 2 first years of the pandemic, and the extent to which the corresponding evidence is still applicable is not fully clear. The pharmacological treatment for severe COVID-19 currently includes systemic corticosteroids (dexamethasone), associated with anti-IL-6 agents and/or the JAK inhibitor baricitinib, and with prophylactic or therapeutic heparin regimen. Remdesivir can be administered. Other agents are not recommended. When oxygen therapy is not sufficient to obtain adequate gas exchange, high-flow nasal therapy or NIV are indicated and can be used alternately. Resources need to be mobilised to provide adequate supportive measures, including palliative care and rehabilitation. Adequate protective measures are needed when providing nebulised therapy.

Rights

This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Downloadable citations

Identifiers

DOI

https://doi.org/10.1183/2312508X.10020423

Repository URI

https://discovery.dundee.ac.uk/en/publications/22e0d2fc-6167-4afa-a547-71d23edd9d9b